<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02839668</url>
  </required_header>
  <id_info>
    <org_study_id>IuliuHatieganu Cluj-Napoca</org_study_id>
    <nct_id>NCT02839668</nct_id>
  </id_info>
  <brief_title>The Impact of Intravenous Anaesthesia on Angiogenesis in Patients With Breast Cancer (TIVA/TCI-BC)</brief_title>
  <acronym>TIVA/TCI-BC</acronym>
  <official_title>The Impact of Intravenous Anaesthesia on Angiogenesis in Patients With Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Iuliu Hatieganu University of Medicine and Pharmacy</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Prof. Dr. I. Chiricuta Institute of Oncology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Iuliu Hatieganu University of Medicine and Pharmacy</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Because neoplastic disease is one of the leading causes of death worldwide and breast cancer
      is one of the most frequent neoplasia among women, the possibility of influencing the
      evolution of patients starting from the moment of surgical intervention using a
      perianesthesic intervention is a scientific topic of high interest. The study will compare
      two anesthetic techniques and their efficiency in lowering the factors that can favorize the
      dissemination of neoplasia and their role in the prevention of postoperative pain. The serum
      level of vascular endothelial growth factor A (VEGF-A) will be determined before and after
      the surgical intervention after using two different types of anesthesia (inhalational and
      intravenous), and the immunohistochemical expression of vascular endothelial growth factor
      receptors (VEGFR) will be determined on the excised tissue. For the two different types of
      anesthesia a continuous infusion of lidocaine 1% will be associated. The study will compare
      the short-term and long term-outcome of the patients assigned the two different types of
      anesthesia and their immediate postoperative evolution .
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will enroll patients with ages between 18 and 80 years old, diagnosed with breast
      cancer but without proof of disease dissemination on medical imaging. After obtaining an
      informed consent the patients will be computer randomized to 4 groups. Each group will
      benefit from a certain type of anesthesia. The first group will be assigned general
      anesthesia using Sevoflurane for maintenance of hypnosis, the second group will be assigned
      general anesthesia with Sevoflurane and a continuous infusion of lidocaine 1%. The thrid
      group will be assigned total intravenous anesthesia using propofol for maintenance of
      hypnosis and the fourth group will be assigned to total intravenous anesthesia with propofol
      and a continuous infusion of lidocaine 1%. Before the surgical procedure a blood sample will
      be drawn from each patient for the measurement of serum vascular endothelial growth factor A
      ( VEGF-A). All the patients will receive pre-medication a night before the intervention with
      low molecular weight heparin (LMWH) and midazolam 5mg the morning of the intervention. For
      the first two groups the anesthetic induction will be conducted using propofol 1,5-2 mg/kg,
      fentanyl 1-3 microg/kg, atracurium 0,5 mg/kg.For the maintenance of anesthesia Sevoflurane
      will be used at a alveolar concentration of 1-1,5 MAC. Intraoperative anesthesia will be
      ensured by using fentanyl boluses of 0.5-2.5 microg/kg and the muscular relaxation needed for
      mechanical ventilation will be maintained using boluses of 10 mg of atracurium. At the end of
      the surgery the neuromuscular blockade will be antagonized with neostigmine 0.05 mg/kg and
      atropine 0.2 mg/kg. For the second group at the induction of anesthesia the patient will be
      administered a bolus of lidocaine 1% of 1.5 mg/kg and a continuous infusion of lidocaine 1% 1
      mg/kg/h will be associated throughout the procedure and 24 h postoperative. The postoperative
      analgesia will be assured by administering acetaminophen 1 g each 8 h and tramadol 25-50 mg
      each 4-6 h as needed. For the third and fourth groups the induction of aneshesia will be made
      using propofol administered by target controlled infusion (TCI) technique with a target
      plasma concentration of 4 microg/ml . Throughout the intervention the plasma concentration of
      propofol will be adjusted with increments of 0.2 microg/ml as to maintain a BIS between
      45-60. To attenuate the response to laryngoscopy the patient will receive a bolus of fentanyl
      1-3 microg/ml. During the intervention fentanyl will be administered in boluses of 0.5-2.5
      microg/kg as needed. Muscular relaxation necessary for intubation will be provided using
      atracurium 0.5 mg/kg at induction of anesthesia and 10 mg boluses during the surgery as
      needed. At the end of the surgery the neuromuscular blockade will be antagonized with
      neostigmine 0.05 mg/kg and atropine 0.2 mg/kg. For the fourth group at the induction of
      anesthesia the patient will be administered a bolus of lidocaine 1% of 1.5 mg/kg and a
      continuous infusion of lidocaine 1% 1 mg/kg/h will be associated throughout the procedure and
      24 h postoperative.Postoperative analgesia will be assured by administering acetaminophen 1 g
      each 8 h and tramadol 25-50 mg each 4-6 h as needed. Throughout the surgical intervention the
      patients will be monitored accordingly to the American Society of Anesthesiologists (ASA)
      standards (electrocardiogram-ECG, heart rate- HR, peripheral capillary oxygen saturation-
      SpO2, non-invasive blood pressure- NIBP, capnography and for the 3rd and 4th groups the
      bispectral index - BIS will be monitored). In the postoperative period non-invasive blood
      pressure -NIBP, heart rate- HR,peripheral capillary oxygen saturation SpO2, intensity of pain
      at 24 and 48 h will be monitored.Vascular endothelial growth factor- VEGF levels will be
      monitored at 24 h postoperative using ELISA technique. Vascular endothelial growth factor
      receptors 1 and 2 (VEGFR1 and VEGFR2) will be determined using immunohistochemical staining.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2016</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>serum concentration of vascular endothelial growth factor A (VEGF-A)</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>pain score</measure>
    <time_frame>1 year</time_frame>
    <description>assesed using visual-analogue scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>survival of patients</measure>
    <time_frame>up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vascular endothelial growth factor receptor 1 and 2 (VEGFR1 and VEGFR2) density</measure>
    <time_frame>at the end of the study</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Sevoflurane</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The patients enrolled in this arm will receive general anesthesia in which the hypnosis will be maintained with Sevoflurane. Postoperative analgesia will be assured by the administration of tramadol and acetaminophen.A 0.05 mg/kg dose of neostigmine will be administered to antagonize the neuromuscular block at the end of surgery.A 0.2 mg/kg dose of atropine will be administered at the end of surgery to attenuate the parasymatomimetic effects of neostigmine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sevoflurane+Lidocaine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The patients enrolled in this group will receive general anesthesia in which the hypnosis will be maintained with Sevoflurane. At the induction of anesthesia the patients will receive a bolus of lidocaine 1% 1.5 mg/kg. A continuous infusion of lidocaine 1% of 1 mg/kg/h will be associated throughout the surgical procedure and until 24 h postoperative. Postoperative analgesia will be assured by the administration of tramadol and acetaminophen.A 0.05 mg/kg dose of neostigmine will be administered to antagonize the neuromuscular block at the end of surgery. A 0.2 mg/kg dose of atropine will be administered at the end of surgery to attenuate the parasymatomimetic effects of neostigmine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TIVA-TCI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The patients enrolled in this group will receive total intravenous anesthesia with propofol using a target controlled infusion technique for the maintenance of hypnosis throughout the surgery. Postoperative analgesia will be assured by the administration of tramadol and acetaminophen.A 0.05 mg/kg dose of neostigmine will be administered to antagonize the neuromuscular block at the end of surgery.A 0.2 mg/kg dose of atropine will be administered at the end of surgery to attenuate the parasymatomimetic effects of neostigmine. The bispectral index- BIS will be monitored throughout the anesthesia.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TIVA-TCI+lidocaine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The patients enrolled in this group will receive total intravenous anesthesia with propofol using a target controlled infusion technique for the maintenance of hypnosis throughout the surgery. At the induction of anesthesia the patients will receive a bolus of lidocaine 1% 1.5 mg/kg. A continuous infusion of lidocaine 1% of 1 mg/kg will be associated throughout the surgical procedure and until 24 h postoperative. Postoperative analgesia will be assured by the administration of tramadol and acetaminophen.A 0.05 mg/kg dose of neostigmine will be administered to antagonize the neuromuscular block at the end of surgery. A 0.2 mg/kg dose of atropine will be administered at the end of surgery to attenuate the parasymatomimetic effects of neostigmine.The bispectral index- BIS will be monitored throughout the anesthesia.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lidocaine</intervention_name>
    <description>Continuous infusion of lidocaine</description>
    <arm_group_label>Sevoflurane+Lidocaine</arm_group_label>
    <arm_group_label>TIVA-TCI+lidocaine</arm_group_label>
    <other_name>lidocaine 1%, lignocaine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sevoflurane</intervention_name>
    <description>maintenance of hypnosis during anaesthesia with sevoflurane</description>
    <arm_group_label>Sevoflurane</arm_group_label>
    <arm_group_label>Sevoflurane+Lidocaine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TIVA-TCI</intervention_name>
    <description>maintenance of hypnosis during anaesthesia with sevoflurane</description>
    <arm_group_label>TIVA-TCI</arm_group_label>
    <arm_group_label>TIVA-TCI+lidocaine</arm_group_label>
    <other_name>Diprivan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acetaminophen</intervention_name>
    <description>administration of 1 g acetaminophen for postoperative analgesia</description>
    <arm_group_label>Sevoflurane</arm_group_label>
    <arm_group_label>Sevoflurane+Lidocaine</arm_group_label>
    <arm_group_label>TIVA-TCI</arm_group_label>
    <arm_group_label>TIVA-TCI+lidocaine</arm_group_label>
    <other_name>paracetamol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tramadol</intervention_name>
    <description>administration of tramadol for postoperative analgesia</description>
    <arm_group_label>Sevoflurane</arm_group_label>
    <arm_group_label>Sevoflurane+Lidocaine</arm_group_label>
    <arm_group_label>TIVA-TCI</arm_group_label>
    <arm_group_label>TIVA-TCI+lidocaine</arm_group_label>
    <other_name>Tramal</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Neostigmine</intervention_name>
    <description>A 0.05 mg/kg dose of neostigmine will be administered to antagonize the neuromuscular block at the end of surgery.</description>
    <arm_group_label>Sevoflurane</arm_group_label>
    <arm_group_label>Sevoflurane+Lidocaine</arm_group_label>
    <arm_group_label>TIVA-TCI</arm_group_label>
    <arm_group_label>TIVA-TCI+lidocaine</arm_group_label>
    <other_name>Prostigmin, vagostigmin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atropine</intervention_name>
    <description>A 0.2 mg/kg dose of atropine will be administered at the end of surgery to attenuate the parasymatomimetic effects of neostigmine</description>
    <arm_group_label>Sevoflurane</arm_group_label>
    <arm_group_label>Sevoflurane+Lidocaine</arm_group_label>
    <arm_group_label>TIVA-TCI</arm_group_label>
    <arm_group_label>TIVA-TCI+lidocaine</arm_group_label>
    <other_name>atropine sulfate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>BIS</intervention_name>
    <description>For the groups receveing TIVA-TCI anesthesia the bispectral index will be monitored</description>
    <arm_group_label>TIVA-TCI</arm_group_label>
    <arm_group_label>TIVA-TCI+lidocaine</arm_group_label>
    <other_name>bispectral index monitor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  diagnosis of breast cancer

          -  ASA risk class I-III

          -  no metastatic disease

        Exclusion Criteria:

          -  hepatic, pulmonary metastasis

          -  type I and II diabetes

          -  rheumatoid arthritis

          -  osteoarthritis

          -  ischemic cardiovascular disease (history of myocardial infarction, angina)

          -  peripheral vascular disease

          -  endometriosis

          -  allergies to lidocaine, fentanyl, propofol, sevoflurane, atracurium, midazolam,
             acetaminophen, tramadol

          -  neuropsychiatric disorders

          -  incapacity of understanding the study

          -  refusal of participation
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Elena V Draghiciu, MD</last_name>
    <phone>+400745318295</phone>
    <email>draghiciuelena@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Daniela Ionescu, Professor</last_name>
    <email>dionescuati@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>IOCN Prof Dr I chiricuta</name>
      <address>
        <city>Cluj-Napoca</city>
        <zip>400015</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+40264598361</phone>
      <email>office@iocn.ro</email>
    </contact>
  </location>
  <location_countries>
    <country>Romania</country>
  </location_countries>
  <reference>
    <citation>Mao L, Lin S, Lin J. The effects of anesthetics on tumor progression. Int J Physiol Pathophysiol Pharmacol. 2013;5(1):1-10. Epub 2013 Mar 8.</citation>
    <PMID>23525301</PMID>
  </reference>
  <reference>
    <citation>Byrne K, Levins KJ, Buggy DJ. Can anesthetic-analgesic technique during primary cancer surgery affect recurrence or metastasis? Can J Anaesth. 2016 Feb;63(2):184-92. Review.</citation>
    <PMID>26497721</PMID>
  </reference>
  <results_reference>
    <citation>Chang YC, Liu CL, Chen MJ, Hsu YW, Chen SN, Lin CH, Chen CM, Yang FM, Hu MC. Local anesthetics induce apoptosis in human breast tumor cells. Anesth Analg. 2014 Jan;118(1):116-24. doi: 10.1213/ANE.0b013e3182a94479.</citation>
    <PMID>24247230</PMID>
  </results_reference>
  <results_reference>
    <citation>Terkawi AS, Sharma S, Durieux ME, Thammishetti S, Brenin D, Tiouririne M. Perioperative lidocaine infusion reduces the incidence of post-mastectomy chronic pain: a double-blind, placebo-controlled randomized trial. Pain Physician. 2015 Mar-Apr;18(2):E139-46.</citation>
    <PMID>25794212</PMID>
  </results_reference>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 18, 2016</study_first_submitted>
  <study_first_submitted_qc>July 20, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 21, 2016</study_first_posted>
  <last_update_submitted>August 21, 2017</last_update_submitted>
  <last_update_submitted_qc>August 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Iuliu Hatieganu University of Medicine and Pharmacy</investigator_affiliation>
    <investigator_full_name>Dr.Draghiciu Elena</investigator_full_name>
    <investigator_title>Universitary Assistant</investigator_title>
  </responsible_party>
  <keyword>breast cancer</keyword>
  <keyword>angiogenesis</keyword>
  <keyword>VEGF</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anesthetics</mesh_term>
    <mesh_term>Lidocaine</mesh_term>
    <mesh_term>Sevoflurane</mesh_term>
    <mesh_term>Atropine</mesh_term>
    <mesh_term>Tramadol</mesh_term>
    <mesh_term>Acetaminophen</mesh_term>
    <mesh_term>Neostigmine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

